October 31, 2014—Orphan drugs will account for almost 20 percent of total worldwide drug sales (excluding generics) by the end of the decade, with year-to-year sales growth more than double that of the overall prescription drug market, the market intelligence firm EvaluatePharma says in a new report.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)